Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-113-2211 OLE in primary Sjögren’s syndrome
2023-503915-14-00Phase 2Completed
- Sponsor
- argenx
- Start
- Sep 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in primary Sjögren's syndrome, sponsored by argenx. Primary endpoint: Incidence and severity of adverse events and adverse events of special interest. Started Sep 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2023-503915-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503915-14-00.